Clinical Efficacy of Modified Si Junzitang in Treatment of Crohn's Disease and Regulation Effect on Inflammatory Factors

ZHANG Hai-yang; SONG Zhan; QIAN Guo-wu; LYU Ke; WANG Xin-wei; DING Shan-shan; WU Zhao-ke

doi:10.13422/j.cnki.syfjx.20181121

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Modified Si Junzitang in Treatment of Crohn's Disease and Regulation Effect on Inflammatory Factors

更新时间：2024-01-04

- Clinical Efficacy of Modified Si Junzitang in Treatment of Crohn's Disease and Regulation Effect on Inflammatory Factors
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 17, Pages: 172-176(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181121
  CLC： R574.62
- Published：2018
- 稿件说明：
移动端阅览
ZHANG Hai-yang, SONG Zhan, QIAN Guo-wu, et al. Clinical Efficacy of Modified Si Junzitang in Treatment of Crohn's Disease and Regulation Effect on Inflammatory Factors[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 172-176.
DOI：

ZHANG Hai-yang, SONG Zhan, QIAN Guo-wu, et al. Clinical Efficacy of Modified Si Junzitang in Treatment of Crohn's Disease and Regulation Effect on Inflammatory Factors[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 172-176. DOI： 10.13422/j.cnki.syfjx.20181121.

摘要

目的：观察四君子汤加味治疗克罗恩病的临床疗效，探讨其对炎症指标的调节作用。方法：将88例克罗恩病患者随机分为观察组和对照组，每组各44例，对照组给予西药常规治疗，观察组在西药常规治疗的基础上予以四君子汤加味治疗，在观察周期8周结束后比较两组临床缓解率和有效率、中医证候疗效、疾病活动评分、炎症程度指标和炎症细胞因子情况并评价安全性。结果：治疗后，观察组临床缓解数和缓解率较对照组显著升高（P<0.01）；在中医证候疗效方面，观察组总有效人数和有效率较对照组显著升高（P<0.01）；观察组临床缓解数和缓解率较对照组明显升高（P<0.05）；观察组无效数和无效率较对照组显著降低（P<0.01）。与本组治疗前相比，两组患者简化克罗恩病疾病活动指数（CDAI）评分项目，红细胞沉降率（ESR），C反应蛋白（CRP）均较本组治疗前显著降低（P<0.01）；治疗后，观察组以上3个指标均较对照组降低（P<0.05）。与本组治疗前相比，两组患者白细胞介素（IL）-6，肿瘤坏死因子（TNF）-α和单核细胞趋化蛋白-1（MCP-1）均较本组治疗前降低（P<0.01）；治疗后，观察组3个指标均较对照组低（P<0.05）。两组患者不良反应发生较少且轻微，两组患者不良反应发生率相比差异不明显。结论：中药四君子汤加味联合西药常规药物治疗不仅可以更好地改善疾病症状，也可以明显改善疾病炎症状态，且安全性良好，临床使用可以取得更好的疗效。

Abstract

Objective:To observe the clinical efficacy of modified Si Junzitang in treatment of Crohn's disease and investigate its regulation effect on inflammatory markers. Method:The 88 patients with Crohn's disease were randomly divided into experimental group and control group

44 cases in each group. Patients in the control group were treated with routine western medicine treatment while patients in experimental group were treated with modified Si Junzitang combined with routine treatment. After 8 weeks

clinical remission rates and effective rates

efficacy of traditional Chinese medicine (TCM) syndrome

disease activity score

inflammation degree index and inflammatory cytokines were compared between two groups and safety was evaluated. Result:After treatment

the number of clinical remission and remission rate in experimental group were significantly higher than those in control group (P<0.01). The total number of effective cases and and effective rate of the TCM syndrome in experimental group were significantly higher than those of the control group (P<0.01). The number of clinical remission cases and remission rate in experimental group were significantly higher than those in control group (P<0.05). The number of ineffectiveness and inefficiency in experimental group were lower than those in the control group (P<0.01). As compared with the conditions before treatment

the simplified Crohn's disease activity index (CDAI) score

erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were significantly lower after treatment in both groups (P<0.01); after treatment

the three indexes above in experimental group were lower than those in control group (P<0.05). The levels of interleukin (IL)-6

tumor necrosis factors (TNF)-α and monocyte chemotactic protein (MCP)-1 after treatment were lower than those before treatment in both groups (P<0.01); these three indexes (P<0.05) in experimental group were lower than those in the control group after treatment (P<0.05). There were few and mild adverse reactions in both groups

with no significant difference between two groups. Conclusion:Modified Si Junzitang combined with western medicine can not only improve the disease symptoms

but also significantly improve the inflammation condition

with good safety and better results in clinical use.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Protective Effect against Helicobacter pylor Gastritis in Mice by Flavonoid Combinations of Alpiniae Officinarum Rhizoma via Inhibition of PI3K/Akt Pathway

Protective Effect of Taohong Siwutang on Cerebral Ischemia-reperfusion Injury Based on A1/A2 Phenotype Transformation of Astrocytes Mediated by JAK2/STAT3 Pathway

Influence of Guizhi Jia Longgu Mulitang on Expression of IL-10 and TNF-α in Insomnia Rats with Sensory Dysfunction Dominated by Lung

Traditional Chinese Medicine Intervention for Ferroptosis in Treatment of Inflammatory Bowel Disease： A Review

Improvement of Skin Barrier and Anti-inflammatory Mechanism of Huangliansan on Atopic Dermatitis in Mice

Related Author

LUO Xin

ZHENG Wuyinxiao

YANG Jingyu

ZHAN Jianting

MA Haoran

YE Xiaochuan

GAN Guopin

LIU Dan

Related Institution

Hubei Engineering Research Center for Traditional Chinese Medicine Processing

Hubei Key Laboratory of Resource and Chemistry of Chinese Medicine，School of Pharmacy， Hubei University of Chinese Medicine

MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials

Anhui Province Key Laboratory of Chinese Medicinal Formula

School of Pharmacy，Anhui University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰